Cumulatively, these findings validate inhibition of NLRP3 in the CNS as a viable therapeutic target in AD and establish the potential in other NDDs, including PD and ALS, and further elucidate the mechanistic contribution of CASM-deficiency and inflammatory priming in neurodegeneration. Here, NLRP3 is linked to amyotrophic lateral sclerosis.